SCHEMBL4222218

SCHEMBL4222218

CC(C)(C)OC(=O)c1ccc(CCc2ccccc2)cc1Nc1c(Cl)cccc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 2/20 0.46
PTGS2 P35354 6/20 0.41
CXCL8 P10145 3/20 0.41
TTR P02766 2/20 0.41
KMT2A Q03164 2/20 0.41
AKR1B10 O60218 1/20 0.41
UGT1A9 O60656 1/20 0.41
TRPA1 O75762 1/20 0.41
ABCB11 O95342 1/20 0.41
MT-CO2 P00403 1/20 0.41
ALB P02768 1/20 0.41
UGT1A6 P19224 1/20 0.41
UGT1A1 P22309 1/20 0.41
PTGS1 P23219 1/20 0.41
CXCR1 P25024 1/20 0.41
ADRA1A P35348 1/20 0.41
AGTR2 P50052 1/20 0.41
NR1I3 Q14994 1/20 0.41
SLC22A6 Q4U2R8 1/20 0.41
NR1H4 Q96RI1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4222764 0.85 AKR1C3 (0.49) P2RX7KMT2AMT-CO2MEN1RECQL
SCHEMBL2275549 0.85 SLC16A3 (0.43) P2RX7KMT2AMEN1LMNA
SCHEMBL4213736 0.83 MEN1 (0.56) P2RX7PTGS2CXCL8TTRKMT2A
SCHEMBL4210622 0.81 AKR1C3 (0.48) KMT2AMEN1RECQLLMNACYP2C9
SCHEMBL4221441 0.81 SIRT2 (0.46) KMT2AMEN1RECQLBLMTDP1
SCHEMBL4217327 0.81 RAB9A (0.42) P2RX7CXCL8KMT2AADRA1AMEN1
SCHEMBL4220608 0.80 ADRA1A (0.46) ADRA1A
SCHEMBL4215772 0.80 SIRT2 (0.45) KMT2AMEN1RECQLBLMTDP1
SCHEMBL4227910 0.80 MPO (0.46) KMT2AMEN1LMNAMAPK1
SCHEMBL4219791 0.79 ADRA1A (0.39) P2RX7KMT2AADRA1AMEN1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 P2RX7 3355/4885PTGS2 441/4885CXCL8 878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.